

# Review of: "[Commentary] Insulin Sensitizers like Metformin and GLP1 with Degludec as Anti-Aging"

Ebaa Alzayadneh<sup>1</sup>

<sup>1</sup> University of Jordan

**Potential competing interests:** No potential competing interests to declare.

It would be interesting to study the relationship between blood glucose lowering drugs and albumin as anti-aging therapy. Despite the title indicates commentary on this relationship, there is a lack of information to support this finding. Most of the previous studies mentioned are referenced inaccurately, or inappropriately placed in this commentary, which requires further review and careful correction. For an example, a study mentioned (ref 7) that used Hepatocyte Growth fragment was delivered in an extracellular matrix derived hydrogel, as a potential treatment for myocardial infarction is not related to the aims of this commentary. Furthermore, Metformin, GLP-1 and Degludec have different mechanisms of actions, thus, how would they be linked to Albumin-antiaging effects. Moreover, insulin itself has growth factor effects with may affect aging somehow that may not be linked to albumin, which was not clarified in this commentary. Albumin modification has been suggested as pro-aging which was not described clearly (do you mean tertiary structure, fragmentation or glycation in diabetes) and if it has a link to insulin it should be emphasized whether its due to lack of insulin or due to hyperglycemia. In summary, the commentary requires further major amendments.

Best regards,

Ebaa M Alzayadneh, BDS, PhD

Department of Physiology and Biochemistry

School of Medicine

The University of Jordan